China Pharma Holdings (CPHI) Non Operating Income (2011 - 2026)
China Pharma Holdings' (CPHI) quarterly Non Operating Income came in at -$25884.0 in Q1 2026, up 3.97% YoY from -$24895.7 in Q1 2025, and down 17.98% on a QoQ basis from -$21940.0 in Q4 2025.
China Pharma Holdings (CPHI) Non Operating Income (2011 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 12 years of Non Operating Income data on file, last reported at -$25884.0 in Q1 2026.
- Quarterly Non Operating Income rose 3.97% year-over-year to -$25884.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52592.0 (up 139.07% YoY) and the FY2025 annual result came in at $51522.0, up 134.93% from the prior year.
- Non Operating Income slipped to -$25884.0 in Q1 2026, from -$21940.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $123753.0 in Q2 2025 to a low of -$136721.0 in Q2 2023.
- A 5-year average of -$51336.6 and a median of -$46609.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income tumbled 66.21% — and 2025, when it jumped 365.51%.
- Tracing CPHI's Non Operating Income over 5 years: stood at -$95172.0 in 2022, then surged by 49.86% to -$47722.0 in 2023, then soared by 40.5% to -$28396.0 in 2024, then climbed by 22.74% to -$21940.0 in 2025, then declined by 17.98% to -$25884.0 in 2026.
- The last three Non Operating Income figures came in at -$25884.0 (Q1 2026), -$21940.0 (Q4 2025), and -$23337.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | China Pharma Holdings | 42.55 Mn | 42.24 Mn | 83,566.00 | -26,278.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25,884.00 |
| Dec 31, 2025 | -21,940.00 |
| Sep 30, 2025 | -23,337.00 |
| Jun 30, 2025 | 123,753.00 |
| Mar 31, 2025 | -26,954.00 |
| Dec 31, 2024 | -28,396.00 |
| Sep 30, 2024 | -32,654.00 |
| Jun 30, 2024 | -46,609.00 |
| Mar 31, 2024 | -39,840.00 |
| Dec 31, 2023 | -47,722.00 |
| Sep 30, 2023 | -64,058.00 |
| Jun 30, 2023 | -136,721.00 |
| Mar 31, 2023 | -78,497.00 |
| Dec 31, 2022 | -95,172.00 |
| Sep 30, 2022 | -102,119.00 |
| Jun 30, 2022 | -108,801.00 |
| Mar 31, 2022 | -117,772.00 |
| Dec 31, 2021 | -332,029.00 |
| Sep 30, 2021 | -64,265.00 |
| Jun 30, 2021 | -71,813.00 |